Despite positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from PBMs. These insurers are often building barriers https://abelmisz665794.aioblogs.com/94751260/company-s-vyndamax-faces-is-meeting-pbm-hurdles-a-copyrightination-of-reimbursement-fights